# Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

> **NCT05704556** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 38 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** VX-548

## Key facts

- **NCT ID:** NCT05704556
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-27
- **Primary completion:** 2024-03-30
- **Final completion:** 2024-03-30
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704556, "Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT05704556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*